{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:56:09Z","timestamp":1776423369170,"version":"3.51.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Scientific and Technological Research Council of T\u00fcrkiye","award":["Grant Number: 123Z989"],"award-info":[{"award-number":["Grant Number: 123Z989"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11805-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:59:14Z","timestamp":1776419954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["STAT3 inhibitor STAT-IN-12 induces apoptosis in mutant-p53 MDA-MB-435 and MDA-MB-231 breast cancer cell lines"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7659-742X","authenticated-orcid":false,"given":"Deniz","family":"\u00d6zdemi\u0307r","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9206-3177","authenticated-orcid":false,"given":"G\u0131yasettin","family":"Baydas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9467-3761","authenticated-orcid":false,"given":"\u00d6zkan","family":"\u00d6zden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1287-9601","authenticated-orcid":false,"given":"Marco","family":"Fidaleo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0244-3767","authenticated-orcid":false,"given":"Can Ali","family":"A\u011fca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"1","key":"11805_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.18388\/pb.2021_518","volume":"70","author":"M Rusin","year":"2024","unstructured":"Rusin M (2024) The p53 protein\u2013not only the guardian of the genome. Postepy Biochem 70(1):71\u201387. https:\/\/doi.org\/10.18388\/pb.2021_518","journal-title":"Postepy Biochem"},{"key":"11805_CR2","doi-asserted-by":"publisher","first-page":"116332","DOI":"10.1016\/j.bcp.2024.116332","volume":"226","author":"G Temaj","year":"2024","unstructured":"Temaj G, Chichiarelli S, Telkoparan-Akillilar P, Saha S, Nuhii N, Hadziselimovic R, Saso L (2024) P53: A key player in diverse cellular processes including nuclear stress and ribosome biogenesis, highlighting potential therapeutic compounds. Biochem Pharmacol 226:116332. https:\/\/doi.org\/10.1016\/j.bcp.2024.116332","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"11805_CR3","doi-asserted-by":"publisher","first-page":"155","DOI":"10.7150\/thno.103376","volume":"15","author":"M Jiang","year":"2025","unstructured":"Jiang M, Fang H, Tian H (2025) Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer. Theranostics 15(1):155\u2013188. https:\/\/doi.org\/10.7150\/thno.103376","journal-title":"Theranostics"},{"issue":"1","key":"11805_CR4","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2(1):a001008. https:\/\/doi.org\/10.1101\/cshperspect.a001008","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"11805_CR5","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu X, li J, Fu M, Zhao X, Wang W (2021) The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther 6(1):402. https:\/\/doi.org\/10.1038\/s41392-021-00791-1","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"11805_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13045-021-01214-y","volume":"14","author":"N Awasthi","year":"2021","unstructured":"Awasthi N, Liongue C, Ward AC (2021) STAT proteins: a kaleidoscope of canonical and non-canonical functions in immunity and cancer. J Hematol Oncol 14(1):198. https:\/\/doi.org\/10.1186\/s13045-021-01214-y","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11805_CR7","doi-asserted-by":"publisher","first-page":"2224625","DOI":"10.1080\/16078454.2023.2224625","volume":"28","author":"L Yin","year":"2023","unstructured":"Yin L, Xu J, Wu W, Niu M, Li Z, Zhu F, Xu K (2023) Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia. Hematology 28(1):2224625. https:\/\/doi.org\/10.1080\/16078454.2023.2224625","journal-title":"Hematology"},{"issue":"11","key":"11805_CR8","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/nrc3818","volume":"14","author":"H Yu","year":"2014","unstructured":"Yu H, Lee H, Herrmann A, Buettner R, Jove R (2014) Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev cancer 14(11):736\u2013746. https:\/\/doi.org\/10.1038\/nrc3818","journal-title":"Nat Rev cancer"},{"issue":"42","key":"11805_CR9","doi-asserted-by":"publisher","first-page":"16975","DOI":"10.1073\/pnas.1315862110","volume":"110","author":"Y Wang","year":"2013","unstructured":"Wang Y, van Boxel-Dezaire AHH, Cheon H, Yang J, Stark GR (2013) STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci 110(42):16975\u201316980. https:\/\/doi.org\/10.1073\/pnas.1315862110","journal-title":"Proc Natl Acad Sci"},{"issue":"1","key":"11805_CR10","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.tips.2015.10.001","volume":"37","author":"C Zhao","year":"2016","unstructured":"Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G (2016) Feedback activation of STAT3 as a cancer drug-resistance mechanism. Trends Pharmacol Sci 37(1):47\u201361. https:\/\/doi.org\/10.1016\/j.tips.2015.10.001","journal-title":"Trends Pharmacol Sci"},{"key":"11805_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3390\/ijms22020603","volume":"22","author":"M Tolomeo","year":"2021","unstructured":"Tolomeo M, Cascio A (2021) The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int J Mol Sci 22:603. https:\/\/doi.org\/10.3390\/ijms22020603","journal-title":"Int J Mol Sci"},{"key":"11805_CR12","doi-asserted-by":"publisher","unstructured":"Romeo MA, Gilardini Montani MS, Benedetti R, Santarelli R, Orazi GD, Cirone M (2020) STAT3 and mutp53 Engage a Positive Feedback Loop Involving HSP90 and the Mevalonate Pathway. Front Oncol 10. https:\/\/doi.org\/10.3389\/fonc.2020.01102","DOI":"10.3389\/fonc.2020.01102"},{"key":"11805_CR13","doi-asserted-by":"publisher","unstructured":"Pham TH, Park HM, Kim J, Hong JT, Yoon DY (2020) STAT3 and p53: Dual target for cancer therapy. Biomedicines 8(12). https:\/\/doi.org\/10.3390\/biomedicines8120637","DOI":"10.3390\/biomedicines8120637"},{"key":"11805_CR14","doi-asserted-by":"publisher","unstructured":"Byun WS, Bae ES, Cui J, Park HJ, Oh DC, Lee SK (2021) Antitumor activity of pulvomycin via targeting activated-STAT3 signaling in docetaxel-resistant triple-negative breast cancer cells. Biomedicines 9(4). https:\/\/doi.org\/10.3390\/biomedicines9040436","DOI":"10.3390\/biomedicines9040436"},{"key":"11805_CR15","doi-asserted-by":"publisher","first-page":"1381251","DOI":"10.3389\/fonc.2024.1381251","volume":"14","author":"L Long","year":"2024","unstructured":"Long L, Fei X, Chen L, Yao L, Lei X (2024) Potential therapeutic targets of the JAK2\/STAT3 signaling pathway in triple-negative breast cancer. Front Oncol 14:1381251. https:\/\/doi.org\/10.3389\/fonc.2024.1381251","journal-title":"Front Oncol"},{"issue":"1","key":"11805_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13046-019-1206-z","volume":"38","author":"JJ Qin","year":"2019","unstructured":"Qin JJ, Yan L, Zhang J, Zhang WD (2019) STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review. J Exp Clin Cancer Res 38(1):195. https:\/\/doi.org\/10.1186\/s13046-019-1206-z","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"11805_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1158\/1078-0432.CCR-24-2920","volume":"31","author":"AM Tsimberidou","year":"2025","unstructured":"Tsimberidou AM, Vining DJ, Arora SP, de Achaval S, Larson J, Kauh J, Kaseb AO (2025) Phase I Trial of TTI-101, a first-in-class oral inhibitor of STAT3, in patients with advanced solid tumors. Clin cancer Res 31(6):965\u2013974. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2920","journal-title":"Clin cancer Res"},{"issue":"1","key":"11805_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13046-024-02949-5","volume":"43","author":"Y Hu","year":"2024","unstructured":"Hu Y, Dong Z, Liu K (2024) Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res 43(1):23. https:\/\/doi.org\/10.1186\/s13046-024-02949-5","journal-title":"J Exp Clin Cancer Res"},{"key":"11805_CR19","doi-asserted-by":"publisher","first-page":"116757","DOI":"10.1016\/j.bmc.2022.116757","volume":"65","author":"YC Liu","year":"2022","unstructured":"Liu YC, Yang YD, Liu WQ, Du TT, Wang R, Ji M, Chen XG (2022) Benzobis(imidazole) derivatives as STAT3 signal inhibitors with antitumor activity. Bioorg Med Chem 65:116757. https:\/\/doi.org\/10.1016\/j.bmc.2022.116757","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"11805_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41418-018-0246-9","volume":"26","author":"F Mantovani","year":"2019","unstructured":"Mantovani F, Collavin L, Del Sal G (2019) Mutant p53 as a guardian of the cancer cell. Cell Death Differ 26(2):199\u2013212. https:\/\/doi.org\/10.1038\/s41418-018-0246-9","journal-title":"Cell Death Differ"},{"issue":"1","key":"11805_CR21","doi-asserted-by":"publisher","first-page":"20","DOI":"10.48138\/cjo.979147","volume":"9","author":"A Do\u011fan","year":"2022","unstructured":"Do\u011fan A, Do\u011fan ANC (2022) Investigation of the effects of sodium phenylpyruvate on pulmonary adenocarcinoma (A549) and mammary adenocarcinoma (MDA-MB-231) on cell lines. Cauc J Sci 9(1):20\u201334. https:\/\/doi.org\/10.48138\/cjo.979147","journal-title":"Cauc J Sci"},{"issue":"5","key":"11805_CR22","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1038\/nprot.2006.339","volume":"1","author":"NAP Franken","year":"2006","unstructured":"Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C (2006) Clonogenic assay of cells in vitro. Nat Protoc 1(5):2315\u20132319. https:\/\/doi.org\/10.1038\/nprot.2006.339","journal-title":"Nat Protoc"},{"issue":"2","key":"11805_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.46810\/tdfd.958756","volume":"10","author":"D \u00d6zdemir","year":"2021","unstructured":"\u00d6zdemir D, \u015eatana K, \u00d6zdemir D, \u00c7iftci M, Agca CA (2021) \u0130fosfamid ve Kurkumin Kombinasyonun K\u00fc\u00e7\u00fck H\u00fccreli D\u0131\u015f\u0131 Akci\u011fer Kanseri H\u00fccresinde Apoptotik Biyobelirte\u00e7ler ve H\u00fccre G\u00f6\u00e7\u00fc \u00dczerine Etkileri. T\u00fcrk Do\u011fa ve Fen Derg 10(2):295\u2013302. https:\/\/doi.org\/10.46810\/tdfd.958756","journal-title":"T\u00fcrk Do\u011fa ve Fen Derg"},{"issue":"5","key":"11805_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.15407\/biotech16.04.034","volume":"16","author":"D \u00d6zdemir","year":"2023","unstructured":"\u00d6zdemir D, Saruhan S, Agca CA (2023) KAN0438757: A novel pfkfb3 inhibitor that induces programmed cell death and suppresses cell migration in non-small cell lung carcinoma cells. Biotechnol Acta 16(5):34\u201344. https:\/\/doi.org\/10.15407\/biotech16.04.034","journal-title":"Biotechnol Acta"},{"issue":"3","key":"11805_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.cbi.2009.11.027","volume":"183","author":"XH Cao","year":"2010","unstructured":"Cao XH, Wang AH, Wang CL, Mao DZ, Lu MF, Cui YQ, Jiao RZ (2010) Surfactin induces apoptosis in human breast cancer MCF-7 cells through a ROS\/JNK-mediated mitochondrial\/caspase pathway. Chem Biol Interact 183(3):357\u2013362. https:\/\/doi.org\/10.1016\/j.cbi.2009.11.027","journal-title":"Chem Biol Interact"},{"key":"11805_CR26","doi-asserted-by":"publisher","unstructured":"Giordo R, Nasrallah GK, Al-Jamal O, Paliogiannis P, Pintus G (2020) Resveratrol inhibits oxidative stress and prevents mitochondrial damage induced by zinc oxide nanoparticles in zebrafish (Danio rerio). Int J Mol Sci 21(11). https:\/\/doi.org\/10.3390\/ijms21113838","DOI":"10.3390\/ijms21113838"},{"issue":"1","key":"11805_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/0471142727.mb2806s111","volume":"111","author":"KH Kim","year":"2015","unstructured":"Kim KH, Sederstrom JM (2015) Assaying cell cycle status using flow cytometry. Curr Protoc Mol Biol 111(1):26\u201328. https:\/\/doi.org\/10.1002\/0471142727.mb2806s111","journal-title":"Curr Protoc Mol Biol"},{"issue":"1","key":"11805_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/13880209.2018.1495748","volume":"56","author":"AA Baharuddin","year":"2018","unstructured":"Baharuddin AA, Roosli RAJ, Zakaria ZA, Tohid SFM (2018) Dicranopteris linearis extract inhibits the proliferation of human breast cancer cell line (Mda-mb-231) via induction of s-phase arrest and apoptosis. Pharm Biol 56(1):422\u2013432. https:\/\/doi.org\/10.1080\/13880209.2018.1495748","journal-title":"Pharm Biol"},{"key":"11805_CR29","doi-asserted-by":"publisher","unstructured":"Agca CA, K\u0131r\u0131c\u0131 M, Nedzvetsky VS, Gundogdu R, Tykhomyrov AA (2020) The effect of tigar knockdown on apoptotic and epithelial-mesenchymal markers expression in doxorubicin-resistant non-small cell lung cancer A549 cell lines. Chem Biodivers 17(9). https:\/\/doi.org\/10.1002\/cbdv.202000441","DOI":"10.1002\/cbdv.202000441"},{"issue":"1","key":"11805_CR30","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-4598-6-24","volume":"6","author":"JP Alao","year":"2007","unstructured":"Alao JP (2007) The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 6(1):24. https:\/\/doi.org\/10.1186\/1476-4598-6-24","journal-title":"Mol Cancer"},{"issue":"2","key":"11805_CR31","doi-asserted-by":"publisher","first-page":"897","DOI":"10.3390\/cancers6020897","volume":"6","author":"RL Carpenter","year":"2014","unstructured":"Carpenter RL, Lo HW (2014) STAT3 Target genes relevant to human cancers. Cancers (Basel) 6(2):897\u2013925. https:\/\/doi.org\/10.3390\/cancers6020897","journal-title":"Cancers (Basel)"},{"key":"11805_CR32","doi-asserted-by":"publisher","first-page":"666505","DOI":"10.3389\/fonc.2021.666505","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Liu Z, Zhou Y, Zeng M, Pan S, Liu H, Zhu H (2021) Identification of a novel transcription factor prognostic index for breast cancer. Front Oncol 11:666505. https:\/\/doi.org\/10.3389\/fonc.2021.666505","journal-title":"Front Oncol"},{"key":"11805_CR33","doi-asserted-by":"publisher","unstructured":"To SQ, Dmello RS, RichardsAK, Ernst M, Chand AL (2022) STAT3 signaling in breast cancer: Multicellular actions and therapeutic potential. Cancers (Basel) 14(2). https:\/\/doi.org\/10.3390\/cancers14020429","DOI":"10.3390\/cancers14020429"},{"key":"11805_CR34","doi-asserted-by":"publisher","unstructured":"Li X, Jiang W, Dong S, Li W, Zhu W, Zhou W (2022) STAT3 Inhibitors: A novel insight for anticancer therapy of pancreatic cancer. Biomolecules 12(10). https:\/\/doi.org\/10.3390\/biom12101450","DOI":"10.3390\/biom12101450"},{"key":"11805_CR35","doi-asserted-by":"publisher","first-page":"122635","DOI":"10.1016\/j.lfs.2024.122635","volume":"346","author":"KN Wang","year":"2024","unstructured":"Wang KN, Zhou K, Zhong NN, Cao LM, Li ZZ, Xiao Y, Bu LL (2024) Enhancing cancer therapy: The role of drug delivery systems in STAT3 inhibitor efficacy and safety. Life Sci 346:122635. https:\/\/doi.org\/10.1016\/j.lfs.2024.122635","journal-title":"Life Sci"},{"key":"11805_CR36","doi-asserted-by":"publisher","unstructured":"Pan L, Chen X, Rassool FV, Li C, Lin J (2022) LLL12B, a novel small-molecule STAT3 inhibitor, induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells. Biomedicines 10(8). https:\/\/doi.org\/10.3390\/biomedicines10082003","DOI":"10.3390\/biomedicines10082003"},{"issue":"6","key":"11805_CR37","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1158\/0008-5472.CAN-09-2468","volume":"70","author":"L Lin","year":"2010","unstructured":"Lin L, Hutzen B, Zuo M, Ball S, Deangelis S, Foust E, Lin J (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70(6):2445\u20132454. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2468","journal-title":"Cancer Res"},{"key":"11805_CR38","doi-asserted-by":"publisher","unstructured":"Cardoso AA, Jiang Y, Luo M, Reed AM, Shahda S, He Y, Fishel ML (2012) APE1\/Ref-1 regulates STAT3 transcriptional activity and APE1\/Ref-1\u2013STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. https:\/\/doi.org\/10.1371\/journal.pone.0047462","DOI":"10.1371\/journal.pone.0047462"},{"issue":"12","key":"11805_CR39","doi-asserted-by":"publisher","first-page":"101822","DOI":"10.1016\/j.isci.2020.101822","volume":"23","author":"L Brambilla","year":"2020","unstructured":"Brambilla L, Lahiri T, Cammer M, Levy DE (2020) STAT3 inhibitor OPB-51602 Is cytotoxic to tumor cells through inhibition of complex I and ROS induction. iScience 23(12):101822. https:\/\/doi.org\/10.1016\/j.isci.2020.101822","journal-title":"iScience"},{"issue":"3","key":"11805_CR40","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1152\/physrev.00026.2013","volume":"94","author":"DB Zorov","year":"2014","unstructured":"Zorov DB, Juhaszova M, Sollott SJ (2014) Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev 94(3):909\u2013950. https:\/\/doi.org\/10.1152\/physrev.00026.2013","journal-title":"Physiol Rev"},{"key":"11805_CR41","doi-asserted-by":"publisher","unstructured":"Pavlyuchenkova AN, Chelombitko MA, Fedorov AV, Kuznetsova MK, Zinovkin RA, Razin E (2023) The distinct effects of the mitochondria-targeted STAT3 inhibitors Mitocur-1 and Mitocur-3 on mast cell and mitochondrial functions. Int J Mol Sci 24(2). https:\/\/doi.org\/10.3390\/ijms24021471","DOI":"10.3390\/ijms24021471"},{"issue":"10","key":"11805_CR42","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1080\/1061186X.2018.1452244","volume":"26","author":"Y Chen","year":"2018","unstructured":"Chen Y, Ji M, Zhang S, Xue N, Xu H, Lin S, Chen X (2018) Bt354 as a new STAT3 signaling pathway inhibitor against triple negative breast cancer. J Drug Target 26(10):920\u2013930. https:\/\/doi.org\/10.1080\/1061186X.2018.1452244","journal-title":"J Drug Target"},{"issue":"7","key":"11805_CR43","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5483\/BMBRep.2019.52.7.152","volume":"52","author":"H Lee","year":"2019","unstructured":"Lee H, Jeong AJ, Ye SK (2019) Highlighted STAT3 as a potential drug target for cancer therapy. BMB Rep 52(7):415. https:\/\/doi.org\/10.5483\/BMBRep.2019.52.7.152","journal-title":"BMB Rep"},{"key":"11805_CR44","doi-asserted-by":"publisher","first-page":"109502","DOI":"10.1016\/j.biopha.2019.109502","volume":"121","author":"Z Liu","year":"2020","unstructured":"Liu Z, Ge X, Gu Y, Huang Y, Liu H, Yu M, Liu Y (2020) Small molecule STAT3 inhibitor, 6Br-6a suppresses breast cancer growth in vitro and in vivo. Biomed Pharmacother 121:109502. https:\/\/doi.org\/10.1016\/j.biopha.2019.109502","journal-title":"Biomed Pharmacother"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11805-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11805-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T09:59:15Z","timestamp":1776419955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11805-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11805"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11805-y","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The consent form is signed by all the participent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors are agreed to publish this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"No ethical approval is required for this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"629"}}